Europe Diabetes Drugs Market by Type, Region, Market Share, Trend Analysis & Forecast Upto 2024

The European diabetes drug market is expected to record a high CAGR of 5.68% during the forecast period (2019 - 2024) due to the growing prevalence of diabetes, growing geriatric population levels, unhealthy diet, and increasing levels of physical inactivity. Diabetes is becoming an increasingly common health condition, which can disable patients and potentially lead to fatal health complications.Europe's diabetes spending is approx. 9% of the total global healthcare expenditure; expenditure on diabetes largely varies among countries in Europe. It ranges from EUR 312 per-capita in the Republic of Macedonia to EUR 6,896 per-capita in Norway.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/19811
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Similarly, prevalence is also widely varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular diseases, blindness, kidney failure, and lower limb amputation. Currently, 30 countries out of 47 are implementing a national plan that includes diabetes individually or within a plan for non-communicable diseases (NCDs). Another ten have announced such plans for the near future. The remaining seven either have joined an international initiative on diabetes, or adopted a political resolution, or are covering diabetes in their national health plans. An increasing number of countries are moving toward plans for NCDs, rather than plans addressing diabetes alone. However, European countries still have to implement a fully comprehensive, multi-sectoral approach to diabetes, including factors from outside the health sector within their diabetes policies.

Competitive Landscape
The market is highly consolidated, with a few significant manufacturers having a global market presence.
Mergers and Acquisitions Among Major Players:
The European Commission and Australian regulatory body approved marketing of Biocon, and the Mylan co-developed drug Insulin Glargine Semglee is boosting the demand in the diabetes market.

Innovations in the Diabetes Drugs Market:
Eli Lilly has submitted an application for Glucagon which can be administered via the nasal route in Europe and the United States if it approved it can be used to treat diabetes.

Request Discount on this report @ https://marketprognosis.com/discount-request/19811
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Scope of the Report
The market is segmented by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by Segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors), and by Geography.

Key Market Trends
Oral Anti-diabetic Drugs and Insulin hold a Significant Market Share
Among the diabetes drugs in the European region, oral anti-diabetic and insulin drugs occupy a significant market share. Of the insulin drugs, basal insulins subsegment's market size is high due to high market penetration. Insulin glargine is the most widely used drug, and it has quite a few biosimilars in the market. SGLT-2 inhibitors and DPP-4 inhibitor drugs are expected to gain a significant market share and record a high CAGR of more than 15% during the forecast period.

Germany & France Alone Occupy More than 30% of Share in European Diabetes Drugs Market
Among the studied countries, Germany is expected to lead the market studied, with a considerable market share of 22%, followed by France. In the GLP-1 segment, Victoza holds the largest market share in the European region, and a similar trend is being observed in Germany as well. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells and suppressing inappropriate elevated glucagon secretion.
The German generics market is vast, and the market for oral anti-diabetic drugs is expected to increase during the forecast period. However, pricing is a major issue in Germany, and many companies have backed-up with their plan to launch insulin in the country. In France, the oral DPP-4 drugs dominate the market, followed by GLP-1 and Insulin.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/19811

Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.